In vitro study on the effects of iron sucrose, ferric gluconate and iron dextran on redox-active iron and oxidative stress

Abstract

Concerns exist that administration of intravenous (i. v.) iron preparations is associated with oxidative stress.

Therefore iron sucrose (CAS 8047-67-4), ferric gluconate (CAS 34098-81-1) and iron dextran (CAS 9004-66-4) were assessed for redox-active iron by a dichlorofluorescein assay and for intracellular reactive oxygen species (ROS) generation and cytotoxicity in HepG2 cells.

Examining each i.v. iron preparation at its maximum concentration achieved following clinically frequently used doses in a 70 kg individual in in vitro experiments, redox-active iron was highest with ferric gluconate, followed by iron dextran and iron sucrose. Interestingly, when the i. v. iron preparations were diluted in human serum instead of buffer, redox-active iron was highest with iron dextran, followed by iron sucrose, and practically disappeared with ferric gluconate. ROS production in HepG2 cells was increased by all i. v. iron preparations. However, in the neutral red cytotoxicity assay all i. v. iron preparations were non-toxic.

In conclusion, ferric gluconate showed the highest increase in intracellular ROS-production in HepG2 cells and the highest amount of redox-active iron in buffer in the in vitro assays. In contrast to the other i. v. iron preparations, redox-active iron from ferric gluconate was rendered completely redox-inactive by serum, indicating that redox-active iron in the various preparations has different chemical properties.

Key words

Hemodialysis - Intravenous iron, cytotoxicity - Liver cells - Oxidative stress - Redox-active iron

• References

• 1 Kooistra MP, Niemantsverdreit EC, van Es A, Mol-Beerman NM, Strycenberg A, Marx JJM. Iron absorption in erythropoietin-treated haemodialysis patients: effects of iron availability, inflammation and aluminium. Nephrol Dial Transplant. 1998; 13: 82-8
• 2 Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant. 1995; 10: 2070-6
• 3 Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am J Kidney Dis. 1999; 34: 21-8
• 4 Mac ICDougall. Present and future strategies in the treatment of renal anemia. Nephrol Dial Trans. 2001; 16 (01) S50-5
• 5 Zager RA, Johnson AC, Hanson SY, Wasse H. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis. 2002; 40: 90-103
• 6 Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Arzneimittelforschung.
• 7 Macdougall IC, Chandler G, Armstrong A, Breen C, Harchowal J, Calvill I. Characterisation of iron availability from three different IV iron preparations in dialysis patients. J Am Soc Nephrol. 1997; 8: 222-
• 8 Sturm B, Goldenberg H, Scheiber-Mojdehkar B. Transient increase of the labile iron pool in HepG2 cells by intravenous iron preparations. Eur J Biochem. 2003; 270: 3731-8
• 9 Sturm B, Laggner H, Ternes N, Goldenberg H, Scheiber-Mojdehkar B. Intravenous iron preparations and ascorbic acid: effects on chelatable and bioavailable iron. Kidney Int. 2005; 67: 1161-70
• 10 Scheiber-Mojdehkar B, Sturm B, Plank L, Kryzer I, Goldenberg H. Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem.-Pharmacol. 2003; 65: 1973-8
• 11 Van DWyck, Anderson J, Johnson K. Labile iron in parenteral iron formulations: a quantitative and comparative study. Nephrol Dial Transplant. 2004; 19: 2674-5
• 12 Esposito BP, Breuer W, Slotki I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Inv. 2002; 32S: 42-9
• 13 Zager RA, Johnson AC, Hanson SY. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int. 2004; 66: 1441-56
• 14 Agarwal R. Transferrin saturation with intravenous irons: an in vitro study. Kidney Int. 2004; 66: 1139-44
• 15 Agarwal R, Vasavada N, Sachs NG, Chase S. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int. 2004; 65: 2279-89
• 16 Scheiber-Mojdehkar B, Lutzky B, Schaufler R, Sturm B, Goldenberg H. Non-transferrin-bound iron in the serum of hemodialysis patients who receive ferric saccharate: no correlation to peroxide generation. J Soc Nephrol. 2004; 15: 1648-55
• 17 Anraku M, Kitamura K, Shinohara A, Adachi M, Suenga A, Maruyama T et al Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int. 2004; 66: 841-9
• 18 Mimic-Oka J, Savic-Radojevic A, Pljesa-Ercegovac M, Opacic M, Simic T, Dimkovic N et al Evaluation of oxidative stress after repeated intravenous iron supplementation. Ren Fail. 2005; 27: 345-51
• 19 Bayes B, Pastor MC, Bonal J, Foraster A, Romero R. Oxidative stress, inflammation and cardiovascular mortality in haemodialysis-role of seniority and intravenous ferrotherapy:analysis at 4 years of follow-up. Nephrol Dial Transplant. 2006; 21: 984-90
• 20 Schaller G, Scheiber-Mojdehkar B, Wolzt M, Puttinger H, Mittermayer F, Horl WH et al Intravenous iron increases labile serum iron but does not impair forearm blood flow reactivity in dialysis patients. Kidney Int. 2005; 68: 2814-22
• 21 Zager RA, Johnson AC, Hanson SY, Lund S. Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release. Am J Physiol Renal Physiol. 2005; 288 (2) F290-7
• 22 Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood. 2003; 102: 2670-7
• 23 Borenfreund E, Puerner JA. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol Lett. 1985; 24: 119-24
• 24 Danielson BG, Salmonson T, Derendorf H, Geisser P. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. Arzneimittelforschung. 1996; 46: 615-21
• 25 Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. 3rd ed. Oxford: Oxford Science Publications 1999
• 26 McCord JM. Iron, free radicals, and oxidative injury. Semin Hematol. 1998; 35: 5-12
• 27 Pakkinen J, Von LBonsdorf, Peltonen S, Grönhagen-Riska C, Rosenlöf K. Catalytically active iron and bacterial growth in serum of hemodialysis patients after i. v. iron-saccharate administration. Nephrol Dial Transplant. 2000; 15: 1827-34